淋巴癌、血管增生、癌症疫苗：藥劑開發策略分析

淋巴癌、血管增生、癌症疫苗：藥劑開發策略分析 是由出版商BioSeeker Group AB在2012年01月所出版的。 這份英文市場調查報告書包含3317 Pages 價格從美金5175起跳。

簡介

本報告針對淋巴癌的藥物開發策略與血管增生及癌症疫苗的機制、目的、影響藥物開發策略為焦點，提供以臨床實驗治療藥物評價法為基礎的評估與藥物開發策略比較，目錄介紹如下。

第1章 淋巴癌

• 本報告範圍
• 以最佳治療結果與投資回收率為前提的治療標的分析
• 新藥登場：開發階段分類淋巴癌藥物目標策略
• 使用中的複合策略：複合策略分類競爭基準
• 淋巴癌治療藥物適應症選擇
• 臨床實驗與分析計劃：淋巴臨床實驗競爭基準
• 免責事項
• 藥物索引
• 企業索引
• 圖表

第2章 血管增生

• 本報告範圍
• 以最佳治療結果與投資回收率為前提的治療目標
• 新藥登場：開發階段分類血管增生藥物目標策略
• 使用中的複合策略：複合策略分類競爭基準
• 藥物影響與血管增生的適應癌症
• 臨床實驗與分析計劃：血管增生實驗競爭基準
• 免責事項
• 藥物索引
• 企業索引
• 圖表

第3章 癌症疫苗

• 本報告範圍
• 以最佳治療結果與投資回收率為前提的治療目標
• 新藥登場：開發階段分類癌症疫苗藥物目的策略
• 使用中的複合策略：複合策略分類競爭基準
• 藥物影響與癌症疫苗的癌症適應症
• 臨床實驗與分析計劃：癌症疫苗臨床實驗競爭基準
• 免責事項
• 藥物索引
• 企業索引

目錄

Abstract

DESCRIPTION

This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Table of Contents

KEY TOPICS COVERED:

Part I: Lymphoma

• 5.1. The Scope of this Report
• 6. Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets)
• 7. Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs)
• 8. Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies)
• 9. Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma)
• 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies)
• 11. Disclaimer
• 12. Drug Index
• 13. Company Index

• Figures: Includes 6 Figures
• Tables: Includes 222 Tables
• Total Number of Pages: 954

Part II: Angiogenesis

• 5.1. The Scope of this Report
• 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets)
• 7. Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs)
• 8. Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies)
• 9. Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications)
• 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators)
• 10. Disclaimer
• 11. Drug Index
• 12. Company Index

• Figures: Includes 7 Figures
• Tables: Includes 300 Tables
• Total Number of Pages: 1227

Part III: Cancer Vaccines

• 5.1. The Scope of this Report
• 6. Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets)
• 7. Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs)
• 8. Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies)
• 9. Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications)
• 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators)
• 11. Disclaimer
• 12. Drug Index
• 13. Company Index

• Figures: Includes 6 Figures
• Tables: Includes 205 Tables
• Total Number of Pages: 659

FEATURED COMPANIES:

This Report Includes the Following Companies:

• 4SC
• Abbott
• Abiogen
• Abraxis BioScience
• AC Immune
• Acceleron Pharma
• Access
• ACT Biotech
• Active Biotech
• Adaptimmune
• Adherex
• Aduro BioTech
• Advanced Cancer Therapeutics
• Advantagene
• Advaxis
• Advenchen
• AEgera
• AEterna Zentaris
• Affimed Therapeutics
• Agennix
• Agenus
• Aida Pharmaceuticals
• Akela Pharma
• Alfa Wassermann
• Alfacell
• Allos Therapeutics
• Alnylam
• AlphaVax
• Ambit Biosciences
• Ambrilia Biopharma
• Amgen
• Amphora
• Angiogen
• Angiogenex
• Angstrom Pharmaceuticals
• Ansaris
• Antisoma
• Apricus Biosciences
• Apthera
• Arana Therapeutics
• Ariad
• Arno Therapeutics
• ArQule
• Array BioPharma
• Ascenta Therapeutics
• Astellas
• Astex Therapeutics
• AstraZeneca
• Attenuon
• Austrianova
• AVEO
• AVI BioPharma
• Bavarian Nordic
• Bayer
• Bellicum Pharmaceuticals
• Benitec
• BioAlliance Pharma
• BioAxone
• Biocompatibles
• Biocon
• BioCryst Pharmaceuticals
• Biogen Idec
• Biolex
• Biostar
• BioVex
• Boehringer Ingelheim
• Bolder BioTechnology
• Borean Pharma
• Bristol-Myers Squibb
• BTG
• Cadila
• Cancer Research Technology
• CDG Therapeutics
• Celecure
• Celera
• Celgene
• Cell Genesys
• Cell Therapeutics
• CellCeutix
• Celldex Therapeutics
• Cellmid
• Celltrion
• Cephalon
• CG Therapeutics
• ChemoCentryx
• Chemokine Therapeutics
• China Sky One Medical
• Choongwae
• Circadian Technologies
• Cornerstone Pharmaceuticals
• Cosmo Pharmaceuticals
• CSL
• Cue Biotech
• CureTech
• Curis
• Cyclacel
• Cylene Pharmaceuticals
• CytImmune Sciences
• Cytochroma
• Cytokinetics
• Daiichi Sankyo
• Dainippon Sumitomo Pharma
• Dara Biosciences
• Deciphera Pharmaceuticals
• Dendreon
• DeveloGen
• Dr Reddy' s
• Dyax
• Dynavax Technologies
• Eisai
• Eleos
• Eli Lilly
• Emergent BioSolutions
• Endocyte
• EntreMed
• Enzon
• Epeius Biotechnologies
• EpiCept
• Epizyme
• Exelixis
• ExonHit Therapeutics
• Facet Biotech
• Favrille
• Five Prime Therapeutics
• Forma Therapeutics
• GammaCan
• Gemin X Biotechnologies
• Genencor
• Genentech
• Generex
• Genmab
• GenOdyssee Pharmaceuticals
• GenPat77
• Genta
• GENTICEL
• Genzyme
• Geron
• Gilead Sciences
• GlaxoSmithKline
• Gliknik
• GlobeImmune
• GlycoGenesys
• Gradalis
• Green Cross
• Hayashibara
• Heber Biotec
• HemaQuest
• Hoffmann-La Roche
• Human Genome Sciences
• Hy BioPharma
• Ichor Medical Systems
• Idera Pharmaceuticals
• IGF Oncology
• ImClone Systems
• ImmunoCellular Therapeutics
• ImmunoFrontier
• ImmunoGen
• Immunomedics
• Immunotope
• ImmuPharma
• Inex
• Innate Pharma
• InNexus Biotechnology
• Inovio
• Intas Biopharmaceuticals
• Intracel
• Introgen Therapeutics
• ISA Pharmaceuticals
• Isis Pharmaceuticals
• Italfarmaco
• Johnson & Johnson
• KAI Pharmaceuticals
• Karus Therapeutics
• Kinex
• Kirin Pharma
• Kissei
• Kringle Pharma
• Kyowa Hakko Kirin
• Lee' s Pharmaceutical
• Leo
• LG Life Sciences
• Ligand
• Lorus Therapeutics
• MacroGenics
• MAT Biopharma
• Meda
• Medical Marketing International
• MediGene
• MedImmune
• Menarini
• Merck & Co
• Merck KGaA
• Mersana Therapeutics
• MethylGene
• Micromet
• MolMed
• Mologen
• Morvus Technology
• Nektar Therapeutics
• Nemod Biotherapeutics
• Neovacs
• Nereus Pharmaceuticals
• Nerviano Medical Sciences
• NewSouth Innovations
• NIH
• Northwest Biotherapeutics
• Novartis
• NovaRx
• Novelix
• Noxxon
• Nycomed Pharma
• Oasmia
• OncoMune
• Onconova
• OncoTherapy Science
• Oncothyreon
• Oncovir
• Onyvax
• OSI Pharmaceuticals
• Otsuka
• Oxford BioMedica
• OXiGENE
• Pepscan Systems
• Pepscan Therapeutics
• PepTx
• Peregrine Pharmaceuticals
• Pfizer
• Pharmacopeia
• Pharmacyclics
• PharmaMar
• Pharmexa
• Pharminox
• Philogen
• PhiloGene
• Pierre Fabre
• Piramal
• Plexxikon
• Portola Pharmaceuticals
• Prima Biomed
• Progen
• Progenics Pharmaceuticals
• ProNAi Therapeutics
• Protein Sciences
• Protherics
• PTC Therapeutics
• Radient Pharmaceuticals
• Reata Pharmaceuticals
• Receptor BioLogix
• Regeneron
• Reliance Life Sciences
• responsif
• Rexahn
• Rigel
• Sanofi-Aventis
• Santaris Pharma
• SBIO
• Scancell
• SciClone Pharmaceuticals
• Seattle Genetics
• Selvita
• Semafore Pharmaceuticals
• Shire
• Simcere Pharmaceuticals
• Spear Therapeutics
• SRI International
• SuperGen
• SuppreMol
• Switch Pharma
• Synageva BioPharma
• SynDevRx
• Takeda
• Tapestry Pharmaceuticals
• TapImmune
• Tau Therapeutics
• Tekmira Pharmaceuticals
• Telik
• TetraLogic Pharmaceuticals
• Teva
• Therion Biologics
• ThromboGenics
• Tigris Pharmaceuticals
• Titan Pharmaceuticals
• ToolGen
• TopoTarget
• Tracon Pharmaceuticals
• Transgene
• Trion Pharma
• UCB
• United Biomedical
• Vaccinex
• Vaxil BioTherapeutics
• Vaxon Biotech
• VaxOnco
• VBL Therapeutics
• Vectura
• VentiRx Pharmaceuticals
• Vertex Pharmaceuticals
• Vical
• Wilex
• Vion Pharmaceuticals
• Viragen
• Virionics
• ViroMed
• Wyeth
• XBiotech
• Xencor
• Xerion
• Yakult Honsha
• Zenotech
• Zensun
• Zenyaku Kogyo
• A Shortlist of Drugs Included are:
• 131I-tositumomab
• ADXS11-001
• AE-37
• aflibercept
• alemtuzumab
• ALVAC-CEA/B7.1
• amrubicin hydrochloride
• apatinib
• ARQ-197
• astuprotimut-r
• AVX-701
• axitinib
• belagenpumatucel-L
• belinostat
• bevacizumab
• bexarotene
• BIBF-1120
• bortezomib
• BP-GMAX-CD1
• brentuximab vedotin
• brivanib alaninate
• Cadi-05
• CB-10-01
• CEA-TRICOM
• cediranib
• CG-201
• cilengitide
• cladribine
• CMLVAX-100
• CTL901
• CTP-37
• CVac
• DCVax-prostate
• denileukin diftitox
• E-75
• elliptinium acetate
• endostatin
• enzastaurin hydrochloride
• epirubicin
• everolimus
• fosbretabulin tromethamine
• fowlpox-PSA vaccine
• galiximab
• GRNVAC1
• GV-1001
• GV-1002
• GVAX
• GVX-3322
• HBP-347
• Her-2/Neu peptides
• ibritumomab tiuxetan
• IGN-101
• ImmunoVEX tri-melan
• IMO-2055
• INGN-225
• INGN-241
• inotuzumab ozogamicin
• interferon (alpha)
• interferon (alpha2b)
• interferon (gamma)
• interferon alfa-2b
• interferon alpha-2b
• irinotecan hydrochloride
• linifanib
• MAGE-3-TK
• ME-103
• MGN-1601
• midostaurin
• mitoxantrone
• motesanib diphosphate
• MSI vaccine
• MVA-BN
• MVA-BN Her-2 vaccine
• Norelin
• obinutuzumab
• oblimersen sodium
• ofatumumab
• Onyvax-105
• OTS-102
• panobinostat
• PANVAC-VF
• patupilone
• pazopanib hydrochloride
• pDOM-PSMA27
• PEP-223
• pixantrone
• poly-ICLC
• PR1:169-177 peptide
• pralatrexate
• PROSTVAC
• PX-104.1
• ramucirumab
• razoxane
• Reditux
• Reximmune-C
• rhIFN-alpha
• ridaforolimus
• rindopepimut
• rituximab
• romidepsin
• SAI-EGF
• sobuzoxane
• sorafenib tosylate
• Stimuvax
• sunitinib malate
• talactoferrin alfa
• temsirolimus
• teniposide
• TG-4001
• TG-4010
• thymalfasin
• tipifarnib
• TroVax
• vandetanib
• verpasep caltespen
• VX-001
• XL-184
• zanolimumab
• ZYC-300

相關商品

癌症相關市場調查報告書

膀胱癌相關的各種合作趨勢:2007-2012年
Bladder Cancer Partnering 2007-2012
價格 : US $ 995
出版日期 : 2012年05月

腦瘤相關的各種合作趨勢:2007-2012年
Brain Cancer Partnering 2007-2012
價格 : US $ 995
出版日期 : 2012年05月

乳癌相關的各種合作趨勢:2007-2012年
Breast Cancer Partnering 2007-2012
價格 : US $ 1695
出版日期 : 2012年05月

BioSeeker Group AB發行的製藥相關市場調查報告書

癌症的蛋白激脢治療上的競爭分析

Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

價格 : US $ 4425

出版日期 : 2012年05月

分析工具：癌症治療的蛋白激脢抗化劑

Analytical Tool - Protein Kinase Inhibitors in Oncology

價格 : US $ 6674

出版日期 : 2012年05月

乳癌、大腸癌、蛋白質激酶抑制劑分析

Triple Analysis: Breast Cancer, Colorectal Cancer and Protein Kinase Inhibitors

價格 : US $ 5175

出版日期 : 2012年05月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!